Physician profile
Emily Aust
NPI 1851624928
$1,315.56
in general payments reported to CMS, 2019-2025
15 companies · $39.00 in 2025
The $39.00 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $728 · 2022: $529 · 2024: $19.50 · 2025: $39.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $58.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $58.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $416.45 | 2021-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $206.12 | 2021-2022 | |
| Lilly USA, LLC | $137.47 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $136.03 | 2021-2022 | |
| Amarin Pharma, INC. | $80.20 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.64 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.91 | 2021-2022 | |
| Pfizer INC. | $39.87 | 2021 | |
| Merck Sharp & Dohme LLC | $39.57 | 2021-2022 | |
| Glaxosmithkline, LLC. | $35.08 | 2022 | |
| Sanofi-Aventis U.S. LLC | $25.14 | 2021-2022 | |
| Mylan Specialty L.P. | $19.92 | 2021 | |
| Abbott Laboratories | $19.87 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.65 | 2021 | |
| Astellas Pharma US INC | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Aust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.